TP53 and hepatocellular carcinoma: performed CRISPR–Cas9‐based synthetic lethality screens to determine that inhibition of MAPK1 increases the sensitivity of hepatoma cells to sorafenib[7] and that pharmacological inhibition of the DNA replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53.[8] In addition, Jin et al.